MSB 2.17% $1.13 mesoblast limited

"Remestemcel-L intravenous infusions have been evaluated in over...

  1. 11,435 Posts.
    lightbulb Created with Sketch. 508
    "Remestemcel-L intravenous infusions have been evaluated in over 1,100 patients in various clinical trials mainly in relation to acute graft versus host disease (aGVHD) in children".

    I'm under the impression the 1,100 patients refer to lung trial only.

    If one were to add up all patients in all msb trials you would get a figure over 3000 with no adverse health outcomes reported to date.

    As to whats going on with sp.

    Australian investors very skittish when investors in US markets can't make up their minds!

    When results come and money starts to flow Aussie Institutions will take an interest and then on route to CSL type valuation,imo.

    Both Patience and patients required.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.